Ralliant (NYSE:RAL) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Ralliant (NYSE:RAL) from a strong-buy rating to a buy rating in a report published on Tuesday.

A number of other brokerages also recently issued reports on RAL. Morgan Stanley boosted their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Truist Financial reaffirmed a “buy” rating and set a $82.00 target price (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. Citigroup increased their price target on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada raised their price objective on shares of Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Trading Down 1.7%

NYSE RAL opened at $71.38 on Tuesday. The stock has a market cap of $7.90 billion, a P/E ratio of -6.58, a price-to-earnings-growth ratio of 2.70 and a beta of 1.60. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The stock has a 50 day simple moving average of $68.36 and a two-hundred day simple moving average of $55.32. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, analysts forecast that Ralliant will post 2.87 earnings per share for the current year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio is -1.84%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC raised its position in shares of Ralliant by 439.9% in the 2nd quarter. Algert Global LLC now owns 126,010 shares of the company’s stock worth $9,278,000 after purchasing an additional 102,670 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Ralliant in the second quarter worth approximately $8,493,000. Globeflex Capital L P purchased a new stake in Ralliant during the 2nd quarter valued at $623,000. First Nebraska Trust Co purchased a new stake in Ralliant during the 2nd quarter valued at $760,000. Finally, Bank of Nova Scotia bought a new position in shares of Ralliant during the 2nd quarter valued at $16,964,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.